Loading...
•
Mar 31, 2023
IRadimed Q1 2023 Earnings Report
IRadimed reported record revenue and increased financial guidance for the full year.
Key Takeaways
IRadimed Corporation announced record revenue of $15.5 million for Q1 2023, representing over 25% year-over-year growth. The company's GAAP diluted EPS was $0.27, and non-GAAP diluted EPS was $0.30. Operating income increased by 30% to $4.0 million. The company also announced increased financial guidance for the full year 2023.
Reported record revenue of $15.5 million for Q1 2023.
GAAP diluted EPS was $0.27 and non-GAAP diluted EPS was $0.30.
Operating income was $4.0 million, a 30% increase.
Increased full-year 2023 financial guidance.
Forward Guidance
The Company expects revenue of $15.6 million to $15.8 million, GAAP diluted earnings per share of $0.27 to $0.29, and non-GAAP diluted earnings per share of $0.30 to $0.32 for the second quarter of 2023. Increased full-year 2023 financial guidance and now expects to report revenue of $62 million to $63.5 million, GAAP diluted earnings per share of $1.13 to $1.21, and non-GAAP diluted earnings per share of $1.26 to $1.35.
Positive Outlook
- Revenue of $15.6 million to $15.8 million is expected for Q2 2023.
- GAAP diluted earnings per share of $0.27 to $0.29 is expected for Q2 2023.
- Non-GAAP diluted earnings per share of $0.30 to $0.32 is expected for Q2 2023.
- Full-year 2023 revenue is expected to be $62 million to $63.5 million.
- Full-year 2023 non-GAAP diluted earnings per share of $1.26 to $1.35 is expected.
Challenges Ahead
- Guidance excludes stock-based compensation expense, net of tax.
- Potential disruptions in the limited supply chain for products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...